A detailed history of Dodge & Cox transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Dodge & Cox holds 3,622,535 shares of ALNY stock, worth $887 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares
3,622,535
Previous 3,780,185 4.17%
Holding current value
$887 Million
Previous $919 Million 8.48%
% of portfolio
0.6%
Previous 0.58%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$233.81 - $287.01 $36.9 Million - $45.2 Million
-157,650 Reduced 4.17%
3,622,535 $996 Million
Q2 2024

Aug 13, 2024

SELL
$143.31 - $247.0 $4.48 Million - $7.73 Million
-31,295 Reduced 0.82%
3,780,185 $919 Million
Q1 2024

May 14, 2024

BUY
$146.51 - $198.2 $20.1 Million - $27.2 Million
137,170 Added 3.73%
3,811,480 $570 Million
Q4 2023

Feb 15, 2024

SELL
$151.41 - $196.57 $11 Million - $14.3 Million
-72,845 Reduced 1.94%
3,674,310 $703 Million
Q3 2023

Nov 14, 2023

SELL
$170.77 - $211.65 $7.24 Million - $8.97 Million
-42,370 Reduced 1.12%
3,747,155 $664 Million
Q2 2023

Aug 14, 2023

SELL
$185.01 - $212.05 $19.4 Million - $22.3 Million
-105,010 Reduced 2.7%
3,789,525 $720 Million
Q1 2023

May 12, 2023

SELL
$182.66 - $235.53 $127 Million - $164 Million
-696,247 Reduced 15.17%
3,894,535 $780 Million
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $55.4 Million - $72 Million
-298,515 Reduced 6.11%
4,590,782 $1.09 Billion
Q3 2022

Nov 10, 2022

SELL
$138.54 - $232.0 $51.2 Million - $85.8 Million
-369,659 Reduced 7.03%
4,889,297 $979 Million
Q2 2022

Aug 12, 2022

SELL
$120.42 - $169.29 $26.1 Million - $36.7 Million
-216,712 Reduced 3.96%
5,258,956 $767 Million
Q1 2022

May 13, 2022

BUY
$127.18 - $173.91 $5.67 Million - $7.76 Million
44,600 Added 0.82%
5,475,668 $894 Million
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $9.41 Million - $12.3 Million
58,968 Added 1.1%
5,431,068 $921 Million
Q3 2021

Nov 15, 2021

SELL
$169.75 - $207.73 $7.11 Million - $8.7 Million
-41,901 Reduced 0.77%
5,372,100 $1.01 Billion
Q2 2021

Aug 13, 2021

BUY
$128.63 - $176.89 $141 Million - $193 Million
1,092,374 Added 25.28%
5,414,001 $918 Million
Q1 2021

May 14, 2021

SELL
$126.83 - $175.69 $40.4 Million - $55.9 Million
-318,286 Reduced 6.86%
4,321,627 $610 Million
Q4 2020

Feb 11, 2021

SELL
$122.97 - $147.0 $4.64 Million - $5.54 Million
-37,700 Reduced 0.81%
4,639,913 $603 Million
Q3 2020

Nov 13, 2020

SELL
$121.19 - $165.49 $3.16 Million - $4.31 Million
-26,058 Reduced 0.55%
4,677,613 $681 Million
Q2 2020

Aug 13, 2020

SELL
$104.21 - $156.44 $40.6 Million - $61 Million
-389,675 Reduced 7.65%
4,703,671 $697 Million
Q1 2020

May 14, 2020

SELL
$93.12 - $133.99 $14.7 Million - $21.2 Million
-157,975 Reduced 3.01%
5,093,346 $554 Million
Q4 2019

Feb 13, 2020

SELL
$74.51 - $124.23 $4.51 Million - $7.51 Million
-60,480 Reduced 1.14%
5,251,321 $605 Million
Q3 2019

Nov 13, 2019

BUY
$70.9 - $87.82 $4.98 Million - $6.17 Million
70,300 Added 1.34%
5,311,801 $427 Million
Q2 2019

Aug 13, 2019

BUY
$65.86 - $92.79 $16 Million - $22.6 Million
243,500 Added 4.87%
5,241,501 $380 Million
Q1 2019

May 14, 2019

BUY
$72.76 - $93.45 $22.4 Million - $28.8 Million
307,750 Added 6.56%
4,998,001 $467 Million
Q4 2018

Feb 14, 2019

BUY
$62.67 - $88.33 $2.17 Million - $3.06 Million
34,600 Added 0.74%
4,690,251 $342 Million
Q3 2018

Nov 14, 2018

BUY
$87.52 - $122.67 $83,144 - $116,536
950 Added 0.02%
4,655,651 $407 Million
Q2 2018

Aug 14, 2018

SELL
$88.31 - $107.8 $3.37 Million - $4.11 Million
-38,140 Reduced 0.81%
4,654,701 $458 Million
Q1 2018

May 14, 2018

SELL
$115.92 - $148.54 $410 Million - $526 Million
-3,538,754 Reduced 42.99%
4,692,841 $559 Million
Q4 2017

Feb 14, 2018

SELL
$114.49 - $139.98 $104 Million - $127 Million
-909,900 Reduced 9.95%
8,231,595 $1.05 Billion
Q3 2017

Nov 13, 2017

BUY
$72.53 - $118.27 $663 Million - $1.08 Billion
9,141,495
9,141,495 $1.07 Billion

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.1B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Dodge & Cox Portfolio

Follow Dodge & Cox and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dodge & Cox, based on Form 13F filings with the SEC.

News

Stay updated on Dodge & Cox with notifications on news.